Abstracts tagged "rheumatoid arthritis (RA) and Disease Activity"

Abstract Number: 514 • 2019 ACR/ARP Annual Meeting
A Pooled Analysis of 1-year Clinical Outcomes Among 6-month Responders and Non-responders from Three Randomized Controlled Studies of TNF Inhibitor Biosimilars in Patients with Rheumatoid Arthritis
Josef Smolen¹, Michael Weinblatt ², Paul Emery ³, Jung Yoon Choe ⁴, Jonathan Kay ⁵, Jieun Lee ⁶, Gihyun Myung ⁶, Hyoryeong Seo ⁶ and Jeehoon Ghil ⁶, ¹Medical University of Vienna, Vienna, Austria, ²Brigham and Women's Hospital, Boston, MA, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁴Division of Rheumatology, Daegu Catholic University Medical Center, Daegu, Republic of Korea, ⁵UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁶Samsung Bioepis Co., Ltd., Incheon, Republic of Korea
Background/Purpose: SB4, SB2, and SB5 are biosimilars of etanercept, infliximab, and adalimumab. Phase III randomized, double-blind studies were conducted to compare efficacy and safety between…
Abstract Number: 2228 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Disease Activity Is Associated with Low Femoral Neck Bone Mineral Density in a Diverse Cohort of Patients
Katherine Wysham¹, Jonathan Graf ², Jane Shofer ³, Dennis Black ², James Andrews ³, Dolores Shoback ² and Patricia Katz ², ¹Veterans Health Administration Puget Sound, Seattle WA, Seattle, ²University of California, San Francisco, San Francisco, CA, ³University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) is an independent risk factor for osteoporosis (OP) and fracture. Although several OP risk factors are well-described in RA, many mechanisms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].